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Racial Variation in Medical Outcomes
among Living Kidney Donors
Krista L. Lentine, M.D., Mark A. Schnitzler, Ph.D., Huiling Xiao, M.S.,
Georges Saab, M.D., Paolo R. Salvalaggio, M.D., Ph.D., David Axelrod, M.D.,
Connie L. Davis, M.D., Kevin C. Abbott, M.D., M.P.H., and Daniel C. Brennan, M.D.
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Lentine at Saint Louis University Center
for Outcomes Research, Salus Center,
4th Fl., 3545 Lafayette Ave., St. Louis, MO
63104, or at lentinek@slu.edu.
N Engl J Med 2010;363:724-32.

Data regarding health outcomes among living kidney donors are lacking, especially
among nonwhite persons.
Methods

We linked identifiers from the Organ Procurement and Transplantation Network
(OPTN) with administrative data of a private U.S. health insurer and performed a
retrospective study of 4650 persons who had been living kidney donors from October 1987 through July 2007 and who had post-donation nephrectomy benefits with
this insurer at some point from 2000 through 2007. We ascertained post-nephrectomy medical diagnoses and conditions requiring medical treatment from billing
claims. Cox regression analyses with left and right censoring to account for observed
periods of insurance benefits were used to estimate absolute prevalence and prevalence ratios for diagnoses after nephrectomy. We then compared prevalence patterns with those in the 2005–2006 National Health and Nutrition Examination
Survey (NHANES) for the general population.

Copyright © 2010 Massachusetts Medical Society.

Results

Among the donors, 76.3% were white, 13.1% black, 8.2% Hispanic, and 2.4% another race or ethnic group. The median time from donation to the end of insurance
benefits was 7.7 years. After kidney donation, black donors, as compared with white
donors, had an increased risk of hypertension (adjusted hazard ratio, 1.52; 95%
confidence interval [CI], 1.23 to 1.88), diabetes mellitus requiring drug therapy
(adjusted hazard ratio, 2.31; 95% CI, 1.33 to 3.98), and chronic kidney disease (adjusted hazard ratio, 2.32; 95% CI, 1.48 to 3.62); findings were similar for Hispanic
donors. The absolute prevalence of diabetes among all donors did not exceed that
in the general population, but the prevalence of hypertension exceeded NHANES
estimates in some subgroups. End-stage renal disease was identified in less than 1%
of donors but was more common among black donors than among white donors.
Conclusions

As in the general U.S. population, racial disparities in medical conditions occur
among living kidney donors. Increased attention to health outcomes among demographically diverse kidney donors is needed. (Funded by the National Institute of
Diabetes and Digestive and Kidney Diseases and others.)
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L

iving kidney transplantation is
considered to offer patients with end-stage
renal disease the best opportunity for dialysis-free survival.1 In 2006, approximately 27,000
transplantations from registered living kidney
donors were performed worldwide,2 and living
donors supplied nearly 40% of kidney transplants
in the United States.3 Most evidence concerning
the safety of living kidney donation for donors
derives from single-center studies with limited
statistical power and few nonwhite donors.4 In a
recent study, investigators at the University of
Minnesota achieved high ascertainment of longterm patient and renal survival and reported no
adverse effects of living kidney donation on life
span or risk of end-stage renal disease, as compared with survey data from the general U.S.
population.5 Notably, in the Minnesota cohort,
98.8% of the patients were white.
Linkage of records from the Organ Procurement and Transplantation Network (OPTN) (as
supplied by the United Network for Organ Sharing) with the Social Security Administration’s
Death Master File recently indicated that although
surgical and long-term mortality were higher
among black donors than among white donors,
the long-term rate of death did not exceed that
of corresponding control subjects in the National
Health and Nutrition Evaluation Survey (NHANES).6
Although racial disparities in the burden and consequences of diabetes mellitus, hypertension, and
chronic kidney disease in the general population
have been extensively documented,7-10 few data
exist concerning long-term medical outcomes
among nonwhite kidney donors.
Currently, the OPTN collects data on living
donors for only 2 years of follow-up,11 and incomplete reporting and donor loss to follow-up are
common,12 owing in part to compliance barriers,
such as cost and inconvenience.13 Thus, addition
al methods for capturing health outcomes among
racially diverse living kidney donors are needed.
To determine longer-term postdonation medical
outcomes independent of a donor’s interaction
with the transplantation center, we linked administrative data from a private insurance provider
with OPTN-supplied identifiers for living donors.
Using these data, we identified postdonation
diagnoses of hypertension, diabetes mellitus,
chronic kidney disease, and cardiovascular disease; investigated variation in the risk of postdonation medical diagnoses, according to socio-

n engl j med 363;8

demographic traits; and estimated the prevalence
of these diagnoses in demographic subgroups. We
also compared relative and absolute prevalence
estimates with those in recent NHANES data.

Me thods
Data Sources and Participant Selection

We assembled our study data by linking OPTN
records for living kidney donors with administrative data from a national private U.S. health insurer. OPTN data include information on all donors and transplant recipients in the United States,
as submitted by OPTN members.14 The Health
Resources and Services Administration (HRSA)
provides oversight on the activities of the OPTN.
After approval by the institutional review board
at Saint Louis University, we linked beneficiary
identifier numbers from the insurer’s electronic
databases, using names and birthdates, with
unique OPTN identifiers for living kidney donors.
Analyses were performed with the use of limited
data sets in compliance with the provisions of
the Health Insurance Portability and Accountability Act with all direct identifiers removed.
Study participants were eligible if they had an
OPTN record of having served as a living kidney
donor from October 1987 through July 2007 and
were eligible for benefits under the participating
insurer after donor nephrectomy at some point
during the period from May 2000 through December 2007, the period of available claims data.
All participants were simultaneously enrolled in
medical and pharmacy benefits with this company exclusively during the study window. U.S.
Census data were incorporated according to
residential ZIP Code at the time of donor nephrectomy.
Outcome Measures

We ascertained medical diagnoses of hypertension, diabetes mellitus, chronic kidney disease,
and cardiovascular disease among living kidney
donors, using billing claims with corresponding
diagnosis codes as listed in the International Classification of Diseases, Ninth Revision, Clinical Modification, similar to algorithms described previously.15-19
We also examined drug-treated hypertension and
diabetes (with either insulin or oral agents) in
pharmacy claims, using drug-category codes.
Stage-specific coding for chronic kidney disease
was introduced in October 2005. Therefore, we
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fined according to the participant’s report of these
diagnoses on the basis of encounters with a doctor or other health care professional.

Right censoring

Statistical Analysis
Window of insurance benefits,
claims data with diagnoses

Figure 1. Schematic Diagram of Linkage of Study Data Sources.
Identifiers from the Organ Procurement and Transplantation Network
(OPTN) were linked to the administrative data of a private U.S. health insurer for 4650 living kidney donors from October 1987 through July 2007.
Post-nephrectomy medical diagnoses and conditions requiring medical
treatment were ascertained from billing claims. Cox regression analyses
with left and right censoring to account for observed periods of insurance
benefits were used to estimate absolute prevalence and prevalence ratios
for diagnoses after nephrectomy. Prevalence patterns were then compared
with those in the 2005–2006 National Health and Nutrition Examination
Survey (NHANES) for the general population. U.S. Census data were incorporated according to residential ZIP Code at the time of donor nephrectomy.

examined diagnoses of chronic kidney disease
of stage 3 to 5 or end-stage renal disease (i.e.,
chronic kidney disease requiring dialysis) in a
prespecified subgroup with insurance eligibility
ending June 2006 or later.

Data sets were merged and analyzed with the use
of SAS for Windows software, version 9.2 (SAS
Institute). Since windows of insurance benefits
varied across the sample, we used Cox regression
with left and right censoring to account for observed periods of insurance benefits to model the
frequency with 95% confidence intervals and correlates with adjusted hazards ratios of prevalent
diagnoses after donor nephrectomy (Fig. 1). The
prevalence of diagnoses 5 years after donor nephrectomy in the full cohort and in prespecified
subgroups was estimated from outcome-specific
Cox models. We estimated correlates of prevalent
diagnoses in the general population using SAS
Proc Survey logistic software to correct for unequal selection probabilities and response rates
in NHANES. The prevalence of medical conditions in subgroups in the general population was
estimated by transforming the logistic-regression
equation. A P value of less than 0.05 was considered to indicate statistical significance.

Baseline Demographic Variables

Demographic data from the OPTN at the time of
donor nephrectomy included age, sex, and race
or ethnic group, as reported by the donor to the
transplantation center. Because the OPTN began
collecting information on predonation hypertension in June 2004, we examined baseline hypertension status in a secondary analysis. An index
of neighborhood socioeconomic status at the time
of nephrectomy was computed from U.S. Census
data linked by ZIP Code, according to methods
used by the Agency for Healthcare Research and
Quality20 (for details, see the Methods section in
the Supplementary Appendix, available with the
full text of this article at NEJM.org).

R e sult s
Demographic Characteristics of Donors

Among 4650 kidney donors in the study cohort,
76.3% were white, 13.1% black, 8.2% Hispanic,
and 2.4% another race or ethnic group (Table 1).
White donors were significantly older at the time
of donation than were nonwhite donors in the
study sample and nationally (P<0.001 by analysis
of variance). All kidney donors underwent nephrectomy between 1987 and 2007, and the median
time from donation to the end of observed insurance eligibility was 7.7 years. The linked donor
sample was similar on the basis of race and sex
to all living kidney donors in the OPTN and to
Comparison Data for the General Population age-standardized estimates in the general popuInformation about race is not recorded by the in- lation in NHANES.
surer and was unavailable for nondonor beneficiaries. Thus, we compared our results with those Frequency and Variation of Medical
of population-based survey data from NHANES,21 Diagnoses
as has been done in other studies of donor out- At 5 years after donation, the estimated prevacomes.5,6 We included participants in the 2005– lence of diagnosed hypertension was 17.8% (95%
2006 NHANES survey who were 20 years of age confidence interval [CI], 15.8 to 20.2), and the
or older. Race or ethnic group in NHANES was estimated prevalence of drug-treated hypertenself-reported. Hypertension, diabetes, chronic kid- sion was 13.6% (95% CI, 11.4 to 15.8). Diagnoses
ney disease, and cardiovascular disease were de- of diabetes and cardiovascular disease were iden726
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Table 1. Demographic Characteristics of Living Kidney Donors in the Study Sample and in the Organ Procurement
and Transplantation Network (OPTN), 1987–2007.*

Characteristic

Living Donors
in the Study Sample
(N = 4650)

Living Donors
in OPTN
(N = 86,107)

Male sex (%)

45.4

42.2

Non-Hispanic white

76.3

70.9

Non-Hispanic black

Race or ethnic group (%)†
13.1

13.1

Hispanic

8.2

11.8

Other

2.4

4.3

81.2

74.4

Related to recipient (%)
Age at donor nephrectomy (yr)
All donors

37.2±10.0

39.3±10.9

Non-Hispanic white

38.2±10.0

40.7±10.9

Non-Hispanic black

33.9±9.0

35.5±9.9

Hispanic

34.3±9.6

35.9±10.4

Other

34.8±10.8

38.1±11.3

Median time from donation to end of insurance eligibility (yr)

7.7

NA

Median duration of insurance eligibility (yr)

2.1

NA

* Plus–minus values are means ±SD. After adjustment for the sampling technique used in the 2005–2006 National
Health and Nutrition Examination Survey (NHANES), 48.1% of respondents represented in the general population
were men, 71.7% were non-Hispanic white, 11.5% were non-Hispanic black, 8.0% were Hispanic of Mexican ancestry,
and 8.8% were another race or ethnic group. NA denotes not applicable.
† Race or ethnic group was self-reported.

tified in 4.0% (95% CI, 2.7 to 5.3) and 3.2% (95%
CI, 2.1 to 4.2) of donors, respectively. Chronic
kidney disease was indicated as a medical diagnosis in the claims of 5.2% (95% CI, 3.7 to 6.8)
of donors by the fifth anniversary of donation.
Older age at donation was associated with an
increased risk of postdonation hypertension of
6% per year (Table 2). As compared with white
kidney donors, black donors had a relative increase of 52% in the risk of diagnosed hypertension and an increase of 31% in the risk of drugtreated hypertension. The risk of diagnosed
hypertension was 36% higher among Hispanic
donors than among white donors, although the
risk of drug-treated hypertension did not differ
significantly between the two groups. Baseline
hypertension was reported in 12 of 399 donors
(3.0%) from June 2004 through 2007; of these
patients, 11 were white, and 1 was Hispanic.
Among donors after nephrectomy, reported predonation hypertension was strongly correlated
with an increased risk of hypertension (adjusted
hazard ratio, 12.2; 95% CI, 5.6 to 26.7) and with
drug treatment for hypertension (adjusted hazard
ratio, 20.9; 95% CI, 8.8 to 49.3). However, the
n engl j med 363;8

inclusion of this variable did not have a significant effect on the association between black race
or Hispanic ethnic background with hypertension
or black race with drug-treated hypertension
after donor nephrectomy. In NHANES data, black
respondents reported receiving a diagnosis of
hypertension more commonly than did white respondents, whereas Hispanic respondents were
less likely than white respondents to report diagnosed hypertension.
The relative frequency of diagnosed diabetes
among donors rose 5% for each increase in year
of age at the time of donation (Table 2). There
were borderline trends toward more frequent diagnoses of diabetes after donation among black
and Hispanic donors than among white donors
(P = 0.05 for both comparisons). Black and Hispanic donors were more than two times as likely
as white donors to have drug-treated diabetes
after kidney donation. In NHANES data, reported
diabetes was more than twice as common among
black and Hispanic respondents as among white
respondents.
The relative risk of medically coded chronic
kidney disease after donation increased 4% per
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Table 2. Adjusted Relative Risk of Hypertension, Diabetes, Chronic Kidney Disease, and Cardiovascular Disease in Living Kidney Donors
and in the General Population, According to Demographic Factors.*
Variable

Hypertension
Living Donors†
Medical Claims

Diabetes
NHANES‡

Drug-Treated

adjusted hazard ratio
(95% CI)

Reported

Living Donors†
Medical Claims

adjusted odds ratio
(95% CI)

Drug-Treated

adjusted hazard ratio
(95% CI)

NHANES‡
Reported
adjusted odds ratio
(95% CI)

Age (per year)

1.06 (1.06–1.07)§ 1.06 (1.05–1.07)§ 1.06 (1.05–1.07)§ 1.05 (1.03–1.06)§ 1.05 (1.03–1.07)§ 1.05 (1.04–1.06)§

Male sex

1.13 (0.98–1.31)

1.21 (1.03–1.43)§ 0.93 (0.82–1.07)

0.91 (0.68–1.22)

1.10 (0.73–1.66)

0.96 (0.71–1.31)

Reference

Reference

Reference

Race or ethnic group
Non-Hispanic white

Reference

Reference

Reference

Non-Hispanic black

1.52 (1.23–1.88)§ 1.31 (1.02–1.68)§ 1.77 (1.47–2.14)§ 1.52 (1.00–2.30)¶ 2.31 (1.33–3.98)§ 2.74 (2.13–3.51)§

Hispanic

1.36 (1.04–1.78)§ 1.03 (0.73–1.46)

0.65 (0.51–0.83)§ 1.65 (1.00–2.74)¶ 2.94 (1.57–5.51)§ 2.34 (1.76–3.12)§

Other

1.13 (0.68–1.85)

0.85 (0.66–1.10)

0.48 (0.20–1.16)

1.35 (0.50–3.67)

2.58 (0.80–8.28)

2.47 (1.52–1.40)§

* Cardiovascular disease is defined as coronary artery disease, angina, congestive heart failure, heart attack, or stroke. CI denotes confidence interval.
† Adjusted hazard ratios for medical diagnoses among donors were calculated by means of multivariate Cox regression with left and right
censoring to account for observed periods of insurance benefits.
‡ Adjusted odds ratios for patient-reported diagnoses in the National Health and Nutrition Examination Survey (NHANES) were calculated by
means of multivariable logistic regression with correction for unequal selection probabilities and response rates.
§ P<0.05.
¶ P = 0.05.

year of age at the time of donation (Table 2).
Black and Hispanic donors were approximately
twice as likely to have diagnosed chronic kidney
disease after nephrectomy as were white donors.
Prespecified subgroup analysis of 2307 donors
who had medical benefits after the introduction
of stage-specific coding for chronic kidney disease showed that donors had a significant increase in the risk of chronic kidney disease of
stage 3 or higher if they were black (adjusted
hazard ratio, 3.60; 95% CI, 1.37 to 9.39; P = 0.009)
or Hispanic (adjusted hazard ratio, 4.23; 95% CI,
1.52 to 11.75; P = 0.006). Chronic kidney disease
requiring dialysis (i.e., end-stage renal disease)
was reported in 2 of 271 black donors (0.7%) and
1 of 197 Hispanic donors (0.5%) in this sub
analysis, as compared with no cases among 1786
white donors (P = 0.02 by Fisher’s exact test for
the comparison between black and white donors
and P = 0.10 for the comparison between Hispan
ic and white donors). The time from donation to
end-stage renal disease ranged from 6.3 to 16.5
years. In NHANES, the relative risk of chronic
kidney disease in black respondents was twice
that in white respondents.
Although reported cardiovascular disease was
significantly more common among black respondents than among white respondents in the general population, we did not detect racial variation
728
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in the prevalence of cardiovascular diagnoses
among kidney donors.
At 5 years after nephrectomy, the prevalence
of diagnosed hypertension varied from 13.9%
among white women who were 35 years of age
at the time of donation to 47.9% among black
men who were 50 years of age at the time of
donation (Table 3). At the same time, the prevalence of diagnosed diabetes varied from 3.2% in
white men who were 35 years of age at the time
of donation to 10.8% in Hispanic women who
were 50 years of age at the time of donation. The
point estimates for the prevalence of diabetes
among black and Hispanic donors were lower
than those in the general population, but the estimated prevalence of hypertension among Hispanic donors was higher than that in the general
population. There was a trend toward increased
point estimates for the prevalence of hypertension, as compared with the general population,
among black male and female donors and white
male donors who were 50 years of age at the
time of donation, but confidence intervals overlapped those of NHANES.
Race, Socioeconomic Indicators, and Medical
Outcomes after Kidney Donation

Census data were linked for 3385 donors (72.8%)
in our study. In this group, the index of socioeco-
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Chronic Kidney Disease
Living Donors†

Cardiovascular Disease

NHANES‡

Living Donors†

NHANES‡

Medical Claims

Reported

Medical Claims

Reported

adjusted hazard ratio
(95% CI)

adjusted odds ratio
(95% CI)

adjusted hazard ratio
(95% CI)

adjusted odds ratio
(95% CI)

1.04 (1.03–1.06)§

1.02 (1.01–1.03)§

1.09 (1.07–1.19)§

1.08 (1.07–1.09)§

1.64 (1.16–2.34)§

0.59 (0.42–0.84)§

2.11 (1.43–3.10)§

1.43 (1.10–1.87)§

Reference
2.32 (1.48–3.62)§

Reference
1.98 (1.34–2.94)§

Reference

Reference

1.15 (0.63–2.11)

1.44 (1.11–1.88)§

1.90 (1.05–3.43)§

1.42 (0.88–2.27)

0.91 (0.37–2.26)

1.04 (0.71–1.52)

1.74 (0.66–4.76)

0.95 (0.31–2.96)

0.49 (0.07–3.54)

0.86 (0.45–1.67)

nomic indicators was significantly less favorable
among black and Hispanic donors than among
white donors (Table 4). However, socioeconomic
indicators were not associated with any study outcome in bivariate or multivariate analyses. For example, an increased score on the socioeconomic
index was not associated with a significant difference in the risk of hypertension (hazard ratio,
1.00; 95% CI, 0.99 to 1.02), diabetes (hazard ratio, 0.99; 95% CI, 0.93 to 1.02), or chronic kidney
disease (hazard ratio, 0.97; 95% CI, 0.92 to 1.01).

Discussion
Long-term health outcomes have not been well
defined among racially diverse living kidney donors. We used administrative insurance data that
were collected in the course of actual practice to
examine medical diagnoses among living kidney
donors, independent of follow-up by the transplantation center. As compared with white donors,
black and Hispanic donors had an increased risk
of hypertension, drug-treated diabetes, and chronic kidney disease after nephrectomy than did
white donors, increases that were not explained
by socioeconomic factors. The absolute prevalence
of diabetes in donors did not exceed that in the
general population, but the prevalence of hypertension was higher than NHANES estimates in
some subgroups. End-stage renal disease was reported in less than 1% of donors but was more
common among black donors than among white
donors. Thus, as in the general U.S. population,7-10
racial disparities in medical conditions appear to
occur among kidney donors.
n engl j med 363;8

We found that black donors had an increased
risk of hypertension, as compared with white
donors, similar to racial disparities in the gener
al population. The Amsterdam Forum’s medical
guidelines for living kidney donors state that the
presence of hypertension at the time of evaluation is a general exclusion to kidney donation,
except in patients with hypertension whose condition is defined as “low risk.”22 According to the
seminal Mayo Clinic study,23 white race is included among low-risk criteria. Recent data from
predominantly white cohorts suggest that there
is an increased risk of hypertension among donors, as compared with the general population,
possibly due to physiological alterations (including hyperfiltration in the remaining kidney and
changes in vascular tone and renin–angiotensin–
aldosterone regulation) or heightened followup.24,25 Hypertension was recently identified in
41% of 39 black donors who were evaluated at an
average of 7 years after nephrectomy at one center.26 In our study, the increased prevalence of
hypertension among Hispanic donors, as compared with the general population, may, in part,
reflect underreporting of hypertension in this
ethnic group, as compared with white respondents, in NHANES. Other studies have reported
decreased rates of hypertension among Hispanic
persons, as compared with non-Hispanic white
persons, on the basis of both self-reporting and
measured blood pressure.8,27-30 Nonetheless, in
our study, the prevalence of hypertension among
Hispanic donors did not exceed that among
black donors. We speculate that medical surveillance after kidney donation may mitigate barriers
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Table 3. Estimated Prevalence of Hypertension and Diabetes among Living Donors 5 Years after Nephrectomy, as Compared
with the General Population, According to Subgroup.
Age at Evaluation, Sex,
and Race or Ethnic Group*
40 Yr
Female

Hypertension
Diabetes
Living Donors†
NHANES‡
Living Donors†
NHANES‡
percent (95% confidence interval)

Non-Hispanic white

13.9 (11.5–16.2)

16.4 (13.3–19.9)

3.5 (2.2–4.8)

3.4 (1.8–6.3)

Hispanic

18.4 (13.4–23.1)

10.4 (8.5–12.7)

5.7 (2.6–8.7)

7.5 (6.0–9.3)

Non-Hispanic black

20.3 (15.8–24.5)

24.0 (21.8–26.3)

5.2 (2.7–7.7)

8.6 (7.2–10.2)

Non-Hispanic white

15.6 (12.9–18.1)

15.5 (12.8–18.5)

3.2 (2.0–4.4)

3.3 (1.7–6.0)

Hispanic

20.6 (14.9–25.8)

9.8 (7.9–12.0)

5.2 (2.3–8.1)

7.2 (5.6–9.3)

Non-Hispanic black

22.7 (17.7–27.4)

24.4 (22.3–26.7)

4.8 (2.4–7.1)

8.5 (6.7–10.6)

Non-Hispanic white

31.5 (27.1–35.7)

32.5 (28.4–36.8)

6.7 (4.4–9.0)

6.9 (5.5–8.7)

Hispanic

40.2 (30.5–48.6)

21.6 (18.1–25.6)

10.8 (4.8–16.4)

14.5 (11.8–17.7)

Non-Hispanic black

43.7 (35.3–51.1)

42.8 (40.0–45.8)

10.0 (5.2–14.6)

16.5 (14.4–18.9)

Non-Hispanic white

34.9 (29.8–39.6)

31.0 (27.7–36.8)

6.2 (3.8–8.4)

6.6 (5.4–8.2)

Hispanic

44.2 (33.3–53.3)

20.5 (16.9–24.5)

9.9 (4.2–15.4)

14.5 (11.8–17.7)

Non-Hispanic black

47.9 (38.5–55.8)

44.3 (41.3–47.5)

9.2 (4.5–13.7)

16.4 (13.3–19.9)

Male

55 Yr
Female

Male

* Values are for living kidney donors who were evaluated 5 years after nephrectomy.
† Diagnoses after kidney donation were ascertained from diagnosis codes on billing claims.
‡ Diagnoses in the National Health and Nutrition Examination Survey (NHANES) were defined by respondents’ reports of diagnoses on the
basis of clinical encounters.

to the recognition of hypertension rather than
differentially affect the risk of hypertension
among Hispanic donors.
As in the general population, diabetes was
more common among black and Hispanic donors,
as compared with white donors. Canadian researchers recently found a substantially higher
risk of diabetes after kidney donation among
aboriginal donors than among white donors,
mirroring the disparities in risk in the local
population.31 However, in our study, the estimated prevalence of diabetes among black or Hispanic donors did not exceed the prevalence
among corresponding subgroups in the general
population. A diagnosis of diabetes at evaluation
should preclude donation,22 and our data support
the finding of a reduction in the absolute prevalence, although not the relative prevalence, of diabetes among black and Hispanic donors, probably as a result of donor-selection practices.
We observed that black and Hispanic donors
had approximately twice the risk of chronic kidney disease as white donors. In NHANES, the
730
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prevalence of chronic kidney disease was also
twice as high among black respondents as among
white respondents and tended to be higher
among Hispanic respondents than among white
respondents. Similarly, the 2008 U.S. Renal Data
System registry reported that the national incidence of end-stage renal disease among black
persons was 3.7 times that among white persons,
and end-stage renal disease among Hispanic
persons was 1.5 times that among non-Hispanic
white persons.32 Recent queries of registrations
of kidney-transplant candidates showed that although 12% of living kidney donors during the
period from 1996 through 2007 were black,
black donors represented 43% of 148 previous
donors who were subsequently listed for kidney
transplantation.33,34 Our data also suggest that
nonwhite donors have an increased frequency of
end-stage renal disease, although the number of
such events was low. We did not detect significant race-related differences in cardiovascular
diagnoses.
Although we found evidence of socioeconomic
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disadvantage for nonwhite donors, the donor’s
socioeconomic status did not correlate with the
studied medical diagnoses. Since all donors had
private health insurance during the observation
period, it may be that possession of insurance
attenuated health disparities that were based on
socioeconomic status. In addition, our socioeconomic measure may have lacked precision, since
we used neighborhood socioeconomic status as
a surrogate for individual status. The exclusion of
uninsured donors may have underestimated medical complications in nonwhite donors,35 since a
lack of health insurance is more common among
nonwhite donors than among white donors.36,37
Our study has inherent limitations, given the
available data and sampling approach. Reasons
for entry into and exit from the insurance plan
are not available, and disenrollment related to
events such as health status cannot be identified.
Outcome measures that were available in the
administrative data differed from those in the
NHANES data. Billing claims have been shown
to provide sensitive measures of diagnoses of
diabetes and cardiovascular disease in other pop
ulations15,19 but probably underrepresent the burden of kidney dysfunction, as compared with
laboratory-based measures.17
On the basis of claims data that may be leftcensored for the absence of insurance benefits
within the available data, we were unable to distinguish incident diagnoses definitively. The subanalysis of the period during which the OPTN
collected baseline data on hypertension suggests
that some centers have allowed more potential
white donors with elevated blood pressure at
evaluation to proceed with donation, as compared
with those of another race or ethnic group. This
finding is consistent with limited data describing white race as a low-risk criterion for hypertension among potential donors.23 Yet despite the
apparent exclusion of potential black kidney donors with reported hypertension at evaluation,
black donors had an increased rate of hypertension after nephrectomy, as compared with white
donors. It is possible that the evaluation and
reporting of normal blood pressure from the
donor-candidacy evaluation to OPTN vary across
centers. The study data also lacked baseline information on body-mass index.
The stringency of living-donor selection has
inherent tensions with the goal of increasing the
organ supply. Black patients with end-stage renal disease have decreased access to transplann engl j med 363;8

Table 4. Variation in Neighborhood Socioeconomic Status Scores among
3385 Living Kidney Donors at the Time of Nephrectomy, According to Race
or Ethnic Group.*
Variable

White

Black

Hispanic

Socioeconomic status index

49.1±5.3

43.9±6.0

43.7±7.6

Income score

24.8±8.5

19.6±7.1

21.2±8.1

Property-value score

14.5±10.3

11.1±6.0

14.5±10.2

Below federal poverty line (%)

9.1

16.4

16.4

Unemployed (%)

9.2

15.4

15.0

College graduate (%)

27.5

21.2

22.5

Education <12th grade (%)

15.7

22.9

26.8

Crowded household (%)

59.9

83.3

89.2

* Plus–minus values are means ±SD. Scores on the socioeconomic status index
were computed for 3385 of 4650 donors (72.8%) for whom linked Census
data were available. Scores for socioeconomic status, income, and property
value are standardized to range from 0 to 100, with higher values indicating a
higher level. Details about the calculation of these scores are provided in the
Supplementary Appendix. P<0.001 for all comparisons of black and Hispanic
donors with white donors, except for the comparison for property-value score
between Hispanic donors and white donors.

tation, including living-donor allografts, as compared with white patients.38,39 As compared with
white candidates for kidney transplantation, black
candidates are less likely to identify potential
living donors, and their potential living donors
are less likely to donate for reasons including
medical exclusion.40 Despite these exclusions
from donation and the demonstrated benefit of
selection for kidney donation in reducing the
absolute risk of some health complications, such
as diabetes, our data show that as in the general
population, black kidney donors remain at increased relative risk for hypertension, diabetes,
and chronic kidney disease, as compared with
white donors. Race and ethnic group should not
be used to discourage donor evaluation, but these
data may increase awareness of variation in longterm outcomes among living donors and of the
need for longer in-depth follow-up of demographically diverse living donors.
The interpretation and reporting of these data are the responsibility of the authors and do not necessarily reflect the official
policy of the OPTN, the Department of Defense, or the National
Institutes of Health.
Supported in part by grants (K08DK073036 and P30DK079333)
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